Listing & Compliance Notices

SMITH MICRO SOFTWARE, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 23, 2025, the Company received a written notice from Nasdaq (the “December Notice”) granting an additional 180 days, or until June 22, 2026, to regain compliance with the Minimum Bid Price Requirement. If at any time before June 22, 2026, the closing bid price of the Company’s Common Stock is at least $1.00 per share for a minimum of ten consecutive business days, unless Nasdaq exercises its discretion to extend this ten-day period, Nasdaq will provide written confirmation stating that the Company has achieved compliance with the Minimum Bid Price Requirement. The December Notice has”

Mediaco Holding Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 19, 2025, MediaCo Holding Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, a”

MSP Recovery, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 28, 2025, the Company received an additional staff determination letter (“Additional Staff Determination”) indicating that the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, the Company is not in compliance with Listing Rule 5550(a)(2). The Staff determined that such non-compliance served as an additional basis for delisting the Company’s securities from Nasdaq. The Company was afforded an opportunity to present its views to the Panel with respect to this additional deficiency at th”

MSP Recovery, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“October 22, 2025, the Company received a Staff Delisting Determination (the “Delisting Notification”), notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1), as the Company’s stockholders’ equity reported in the Company’s Form 10-K for the year ended December 31, 2024, was below the required minimum of $2.5 million, and the Company did not meet the alternative compliance standards, relating to the market value of listed securities of $35 million or net income from c”

Luminar Technologies, Inc./DE received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“December 17, 2025, Luminar Technologies, Inc. (the “Company”) was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that Nasdaq had determined to delist the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”) in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM‐5101-1 as a result of the Company’s commencement of voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) on December 15, 2025 (the “Chapter 11 Cases”). Nasdaq further indicated that trading of the Common Stock”

Wheels Up Experience Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 17, 2025, Wheels Up Experience Inc. (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual (“Section 802.01C”), which requires listed companies to maintain an average closing price per share of at least $1.00 over a consecutive 30 trading-day period. The Company has six months after receipt of the Notice (the “Cure Period”) to regain compliance with Section 802.01C, which requires that during the Cure Period the Company’s Class A common stock, $0.0001 par v”

Bark, Inc. received a nyse delisting notice notice regarding other (rules 802.01D).

“December 15, 2025, BARK, Inc. (the “Company”) received notice from the New York Stock Exchange (the “NYSE”) that the NYSE has determined to (i) commence proceedings to delist the Company’s warrants (the “Warrants”) and (ii) immediately suspend trading in the Warrants due to “abnormally low selling price” levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. Each Warrant is presently exercisable for one share of the Company’s common stock at an exercise price per share of $11.50, ticker symbol “BARK-WS.” The Company does not intend to appeal the NYSE determination. To effect th”

IO Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 17, 2025, IO Biotech, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market, and the Company’s commo”

VerifyMe, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 12, 2025, VerifyMe, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until June 10, 2026, in which to regain compliance with the minimum bid price requirement.”

Neuphoria Therapeutics Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5620(a)).

“ompany was not in compliance with Nasdaq Listing Rule 5620(a) (the “ Listing Rule ”) as a result of the Company’s failure to hold a qualified annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June”

Cosmos Health Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 11, 2025, Cosmos Health Inc. (the “Company”) received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price of $1.00 per share for thirty (30) consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). The Company has one hundred eighty (180) calendar days from December 11, 2025, to regain compliance by maintaining the closing bid price of the Company’s common stock of at least $1.00 per share for a minimum of ten (10) consecutive business days. In the event the Company cannot otherwise regain compliance with the Lis”

Cambium Networks Corp received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“December 12, 2025, Cambium Networks Corporation (“Cambium” or the “Company”) received a partial compliance letter (the “Partial Compliance Letter”) from the Nasdaq Hearings Panel (the “Hearings Panel”) confirming the Company is in compliance with the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”), although it remains non-compliant with the Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Rule”). The Hearings Panel also confirmed that it will maintain jurisdiction over the Company until April 8, 2026. In addition, per Nasdaq Listing Rule 5815(d)(4)(B), the Company will be sub”

Cambium Networks Corp received a nasdaq compliance regained notice regarding minimum bid price (rules 5450(a)(1)).

“December 12, 2025, Cambium Networks Corporation (“Cambium” or the “Company”) received a partial compliance letter (the “Partial Compliance Letter”) from the Nasdaq Hearings Panel (the “Hearings Panel”) confirming the Company is in compliance with the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”), although it remains non-compliant with the Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Rule”). The Hearings Panel also confirmed that it will maintain jurisdiction over the Company until April 8, 2026. In addition, per Nasdaq Listing Rule 5815(d)(4)(B), the Company will be sub”

Reliance Global Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 12, 2025, Reliance Global Group, Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on the Nasdaq Capital Market. The notification of noncompliance had no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market under the sym”

ZYNEX INC received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“December 17, 2025, the Company received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined to delist the Company’s common stock as a result of the Chapter 11 Cases. Pursuant to Nasdaq listing rules, the Company has the right to appeal Nasdaq’s delisting determination. ​ The Notice further advises that Nasdaq will suspend trading of the Company’s common stock at the opening of business on December 24, 2025 and that Nasd”

Azitra, Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(ii)).

“December 16, 2025, Azitra, Inc. (the “Company”) received notice (the “Letter”) from the NYSE American LLC (“NYSE American”) that it had accepted the Company’s plan (the “Plan”) to regain compliance with the NYSE American’s continued listing standards regarding the minimum stockholders’ equity requirement of Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) and granted a plan period through April 1, 2027 (“Plan Period Deadline”). As previously reported, on October 1, 2025, the Company received a letter from the NYSE American stating that the Company is not in complian”

Vestand Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 12, 2025, Vestand Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Nasdaq Listing Qualifications Department (the “Nasdaq Staff”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s Class A Common Stock on the Nasdaq Capital Market under the symbol “VSTD.” The Company is currently m”

Vivakor, Inc. received a nasdaq deficiency notice notice regarding other (rules 5635(d)).

“December 11, 2025, Vivakor, Inc., a Nevada corporation (the “Company”), received a written notification (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that based on the Staff’s review of the Company’s issuances of shares of common stock and prefunded warrants in connection with the Company’s registered direct offerings conducted in October 2025, the Staff has determined that the Company failed to comply with Nasdaq Listing Rule 5635(d) in relation to certain of the offerings, which requires prior shareholder approval fo”

INTELLIGENT BIO SOLUTIONS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 15, 2025, Intelligent Bio Solutions Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that because the closing bid price for the Company’s common stock was below $1.00 per share for the last 30 consecutive business days, the Company did not meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common”

Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).

“YSE’s determination. Trading in the Company’s Common Stock will be unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock remains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026, and continued compliance with the NYSE’s other continued listing requirements.”

Vicarious Surgical Inc. received a nyse delisting notice notice regarding other (rules 802.01D).

“December 15, 2025, the NYSE notified the Company that the NYSE has determined to (a) commence proceedings to delist the Company’s warrants, with thirty warrants exercisable for one share of Common Stock, at an exercise price of $345.00 per share, and listed to trade on the NYSE under the symbol “RBOT.WS” (the “Public Warrants”) and (b) immediately suspend trading in the Public Warrants due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Common Stock w”

Wellgistics Health, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 9, 2025, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until June 8, 2026 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by June 8, 2026, the Company may be eligible for an additional 180-day period to reg”

IROBOT CORP received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“December 15, 2025, iRobot Corporation (the “Company”) was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that Nasdaq had determined to delist the Company’s common stock, par value $0.01 per share (the “Common Stock”). Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM‐5101-1 as a result of the Company’s commencement of voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (“Chapter 11”) on December 14, 2025. The Company does not intend to appeal”

CHEGG, INC received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 12, 2025, Chegg, Inc. (the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing share price of the Company’s common stock as of December 11, 2025 was less than $1.00 over a consecutive 30 trading-day period. As required by the NYSE, the Company intends to notify the NYSE timely of its intent to regain compliance with the NYSE minimum share price requirement, which may include, if necessary, effecting a reverse stock split, subject to approval by the board of d”

CarParts.com, Inc. received a nasdaq extension granted notice regarding minimum bid price.

“December 15, 2025, the Nasdaq Listing Qualifications department approved the Company’s request to transfer the listing of the Company’s shares of common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will take effect at the opening of business on December 16, 2025. The transfer of the Company’s listing to The Nasdaq Capital Market is not expected to have any immediate effect on trading in shares of the Company’s common stock. The Company’s shares will continue to trade uninterruptedly under the symbol “PRTS.” The Nasdaq Capital Market operates in substa”

Trinseo PLC received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 12, 2025 Trinseo PLC (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company is not currently in compliance with two of the NYSE’s continued listing standards (the “Listing Standards”). ​ First, the Notice indicated that the Company was not currently in compliance with the Listing Standard set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than”

Trinseo PLC received a nyse deficiency notice notice regarding market value (rules 802.01B).

“December 12, 2025 Trinseo PLC (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company is not currently in compliance with two of the NYSE’s continued listing standards (the “Listing Standards”). ​ First, the Notice indicated that the Company was not currently in compliance with the Listing Standard set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than”

Boxlight Corp received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1)).

“l for Mr. Crew’s years of service and contributions to the board. Item 3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or Requirement; Transfer of Listing. Mr. Crew’s resignation has resulted in the Company not being in compliance with The Nasdaq Capital Market (“Nasdaq”) Rule 5605(b)(1), which requires that a majority of the Board of Directors must be comprised of independent directors as defined in Nasdaq listing standards. Pursuant to Nasdaq Rule 5605(b)(1)(A), the Company has 180 days from the date of Mr. Crew’s resignation, or until June 9, 2026, to cure this noncomp”

Trade Desk, Inc. received a nasdaq deficiency notice notice regarding other (rules 5640).

“edule 14A dated July 24, 2025. On October 15, 2025, the Nasdaq Staff contacted the Company regarding the Articles Amendment and application of the Voting Rights Rule thereto. The Nasdaq Staff concluded that it was appropriate to close the matter with the Letter issued in accordance with Nasdaq Rule 5810(c)(4). Accordingly, with the issuance of the Letter, the matter is closed by the Nasdaq Staff, with no further action to be taken on its part. Although the Company does not concur that the Articles Amendment violated the Voting Rights Rule, it welcomes Nasdaq’s closing of this matter and does n”

ALLETE INC received a nyse delisting notice notice regarding other.

“December 15, 2025 SECTION 3 – SECURITIES AND TRADING MARKETS Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth under the Introductory Note of this Current Report on Form 8-K is incorporated by reference in this”

zSpace, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 11, 2025, zSpace, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the continued listing requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1.00. Based on the Staff’s review of the Company’s closing bid price, the Company’s closing bid price was below $1.00 for the previous 30 consecutive business days. The Notice has no immediate effect on”

Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“August 25, 2025, Nasdaq notified the Company that it no longer satisfied Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq granted the Company 180 calendar days, through February 23, 2026, to regain compliance with the Bid Price Rule, which requires that the closing bid price of the Company’s ordinary shares be at least $1.00 for a minimum of 10 consecutive business days. The Company remains out of co”

Aterian, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 9, 2025, Aterian, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Notice”). The Bid Price Notice has no immediate effect”

System1, Inc. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“December 8, 2025 System1, Inc. (the "Company") received a letter from the New York Stock Exchange (the "NYSE") notifying the Company that it is currently not in compliance with Section 802.01B of the NYSE Listed Company Manual because as of December 5, 2025, the Company’s 30 trading-day average market capitalization was less than $50 million and its last reported stockholder’s equity as of September 30, 2025 was less than $50 million. The Company has a period of 18 months to cure the market capitalization and/or stockholder’s equity deficiencies, subject to NYSE's approval of the Company’s bus”

GRAPHJET TECHNOLOGY received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2), 5450(b)(3)(C)).

“inued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on November 11, 2025, the Hearings Panel of The Nasdaq Stock Market LLC (the “Panel”) determined to delist the Company’s Class A ordinary shares from The Nasdaq Global Market due to deficiencies under Nasdaq Listing Rules 5450(b)(2) (market value of listed securities) and 5450(b)(3)(C) (market value of publicly held shares). The delisting became effective on November 13, 2025. On November 25, 2025, the Company timely appealed the Panel’s decision to the Nasdaq Listing and Hearing Review Council (the “Council”) purs”

Nakamoto Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 10, 2025, Kindly MD, Inc., a Utah corporation (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. The notice has no present impact on the listing of the Company’s securities, and the Company’s common stock continues to t”

XCF Global, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 9, 2025, XCF Global, Inc. (the “Company”) received a written notification (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on the Nasdaq Capital Market. The Notice stated that the bid price of the Company’s common stock had closed below $1.00 per share for 30 consecutive business days, from October 27, 2025 to December 8, 2025, and that, in accor”

Northann Corp. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i)).

“December 8, 2025, Northann Corp. (the “Company”) received a letter (the “Letter”) from the staff of NYSE American LLC (the “Exchange”) stating that the Company was not in compliance with the Exchange’s continued listing standards under Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”), as it had stockholders’ equity of approximately $1.8 million as of September 30, 2025, and losses from continuing operations and/or net losses in two of its three most recent fiscal years ended December 31, 2024. Section 1003(a)(i) of the Company Guide requires a listed company to have”

Planet Green Holdings Corp. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

“December 8, 2025, Planet Green Holdings Corp. (the “Company”) received a notice from the New York Stock Exchange (“NYSE”) that it is below the continued listing criteria under Sections 1003(a)(i), (ii), and (iii) of the NYSE's listing standards set forth in Part 10 of the NYSE American Company Guide (“Company Guide”), because the Company reported stockholders’ deficit of ($573,528) at September 30, 2025, and has had losses in its five most recent fiscal years ended December 31, 2024. The Company is also not currently eligible for any exemption in Section 1003(a) of the Company Guide from the s”

Senmiao Technology Ltd received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 1, 2025, we received a letter from the listing qualifications staff (the “ Staff ”) of Nasdaq informing us that, as reported in our quarterly report on Form 10-Q for the period ended September 30, 2025, because our stockholders’ equity was ($132,073), as of September 30, 2025, we did not meet the alternatives of market value of listed securities or net income from continuing operations, and we no longer comply with the Listing Rule. We have 45 calendar days to submit a plan to the Staff to regain compliance. If our plan is accepted, we may be granted an extension of up to 180 calendar”

PharmaCyte Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A), 5810(c)(3)(H)).

“In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until June 1, 2026 (the “Compliance Date”), to regain compliance”

aTYR PHARMA INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. In acc”

XWELL, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 1, 2025, XWELL, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between October 17, 2025, to November 28, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market (“Nasdaq”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until June”

Ubiquiti Inc. received a nyse noncompliance notice notice regarding audit committee (rules 303A.07(a), 10A-3, 303A.02).

“December 4, 2025, the Company received official notice of non-compliance from the NYSE with respect to this deficiency. The Company expects to appoint, as soon as practicable, an additional member to the Board and audit committee who meets the independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the Listed Company Manual. Upon appointing such new member of the Board and the audit committee, the Company will regain compliance with Section 303A.07(a) of the Listed Company Manual.”

INTENSITY THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 4, 2025, the “Company received a second letter (the “December 2025 Nasdaq Letter”) from Nasdaq stating that the Company is eligible for an additional 180 calendar days, or until June 1, 2026, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Staff of the Nasdaq (the “Staff”) determined that the Company is eligible for the second 180 calendar day period, or until June 1, 2026, to regain compliance with the Rule based on the Staff’s determination that the Company must continue to meet the continued listing requirement”

Reborn Coffee, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1), 5810(c)(3)(A), 5810(b)).

“and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Capital Market. This Letter was sent pursuant to an earlier notification letter dated May 29, 2025, warning the Company that it was out of compliance with Nasdaq Listing Rule 5550(b)(1), which requires that the Company maintain stockholders’ equity of at least $2,500,000 (the “Equity Rule”). The Company was provided with 180 calendar days, or until November 25, 2025, to regain compliance pursuant to Rule 5810(c)(3)(A). Pursuant to the procedures set forth in the Nasdaq L”

Aditxt, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 1, 2025, Aditxt, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, based upon the stockholders’ equity reported by the Company in its Form 10-Q for the period ended September 30, 2025, the Company was no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a company to maintain a minimum of $2,500,000 in stockholders’ equity, a market value of listed securities of at least $35 million, or net income from continuing operations of $500,000 in the most recently”

Cambium Networks Corp received a nasdaq hearing update notice regarding late filing (rules 5450(a)(1), 5250(c)(1)).

“December 3, 2025, Cambium Networks Corporation (the “Company”) received a decision (the "Decision Letter") from the Nasdaq Hearings Panel (the “Hearings Panel”) granting the Company’s request for continued listing of the Company’s Ordinary Shares on The Nasdaq Global Market, subject to the Company demonstrating compliance with the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”) and the Nasdaq Listing Rule 5250(c)(1) (the “Filing Rule”), and certain other conditions, including the Company demonstrating compliance with the Filing Rule on or before April 16, 2026. As previously disc”

Fly-E Group, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 25, 2025, Fly-E Group, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the listing qualifications staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it currently does not satisfy Listing Rule 5250(c)(1), as a result of not having timely filed with the U.S. Securities and Exchange Commission (the “ Commission ”) its Form 10-Q for the period ended September 30, 2025 (the “ Form 10-Q ”). The Notice is a notification of deficiency, not of imminent delisting, and has no immediate effect on the listing or trading of the Compan”

ADDENTAX GROUP CORP. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 2, 2025, Addentax Group Corp. (the “Company”) received a letter from the Listings Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share of its common stock was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Nasdaq letter does not result in the immediate delisting of the Company’s shares of common stock, and the shares will continue to trade uni”